https://www.selleckchem.com/EGFR(HER).html
After multikinase inhibitor approval, patients with small tumors, extrathyroidal extension, positive lymph nodes, or metastases were more likely to receive systemic therapy (P less then .05). The 5-year overall survival between pre and postmultikinase inhibitor groups, for those who received systemic therapy (n = 288), was similar (P = .58), even when restricted to patients with distant metastases (P = .55). Conclusion After approval of multikinase inhibitors, physicians broadened the criteria for systemic therapy. Prescription rates have sinc
Like
Comment
Share
